Niagen Bioscience Delivers Strong Q3: 33% Sales Growth and Expanded Clinical Reach Lead to Upgraded Full-Year Outlook
Headline Results: 33% Jump in Sales, Sharply Higher Profitability
Niagen Bioscience (NASDAQ:NAGE) posted impressive third-quarter 2025 results, highlighted by a 33% year-over-year rise in net sales to $34.0 million. The company also reported a net income of $4.6 million, marking a substantial increase from $1.9 million a year earlier. Adjusted EBITDA surged 120% to $6.4 million, and gross margins rose to 64.5%, up 100 basis points. This robust performance reflects strong demand for both its flagship Tru Niagen® product and broader NAD+ category leadership.
Revised Outlook: Guidance Raised to 25–30% Growth on Momentum Across Channels
Building on Q3 strength, management reaffirmed and raised its 2025 full-year net sales growth target to 25%–30% (up from a prior range of 22%–27%). E-commerce gains and expanded B2B partnerships are fueling this momentum, while operating leverage is helping to improve sales and marketing efficiency. The outlook now also includes expectations for continued gross margin improvement and tighter cost discipline.
Profitability and Operational Highlights Show Enhanced Efficiency
The third quarter saw marked gains across major metrics:
| Metric | Q3 2025 | Q3 2024 | Change |
|---|---|---|---|
| Net Sales | $34.0M | $25.6M | +33% |
| Gross Margin | 64.5% | 63.5% | +100 bps |
| Net Income | $4.6M | $1.9M | +141% |
| Adjusted EBITDA | $6.4M | $2.9M | +120% |
| Cash & Equivalents | $64.3M | $44.7M (Dec. '24) | +44% |
Sales and marketing expenses, as a percentage of net sales, dropped by 170 basis points to 25.8%, illustrating greater cost efficiency even as the company ramped up investment for brand growth. Operating income more than doubled, and net cash from operations in the first nine months soared to $12.8 million, further solidifying Niagen’s balance sheet.
Expansion Moves: Digital Platform Launch and Nationwide Clinical Growth
Q3 brought key strategic advances. Niagen launched AboutNAD®, a next-generation digital platform aggregating cutting-edge NAD+ research for consumers, clinicians, and scientists—aimed at fortifying its role as a scientific authority and broadening digital engagement.
On the distribution front, the rollout of pharmaceutical-grade Niagen Plus™ IV and injectable therapies expanded to over 1,000 clinics nationwide, including more than 50 iCRYO locations. This growth accelerates access to clinical-grade NAD+ therapies and cements partnerships with healthcare providers seeking advanced wellness offerings.
Science and Legal Wins Reinforce Brand Credibility
Beyond numbers, Niagen strengthened its evidence-based positioning by successfully defending against unsubstantiated efficacy claims in the NAD+ category. The company prevailed in a National Advertising Division challenge, reinforcing the critical need for credible scientific support behind NAD+ product claims—a development that further differentiates its leadership in this sector.
Key Takeaways: Operational Momentum, Digital Innovation, and Raised Guidance
Niagen’s third-quarter results paint a picture of sustained top-line growth, improved margins, and forward-looking strategic initiatives. Upgraded guidance points to confidence in underlying demand, powered by innovation in both product development and digital infrastructure. As the NAD+ supplement category attracts increasing attention from health-conscious consumers and providers, Niagen’s disciplined cost management, scientific rigor, and expanding clinical footprint set the stage for further growth.
For those tracking high-growth health and biotech stories, Niagen Bioscience’s mix of financial strength, scientific credibility, and execution on expansion is one to watch as the company heads into the end of 2025.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI